Welcome to our dedicated page for Avalo Therapeutics news (Ticker: AVTX), a resource for investors and traders seeking the latest updates and insights on Avalo Therapeutics stock.
Avalo Therapeutics, Inc. reports developments for a clinical-stage biotechnology company focused on IL-1β-based treatments for immune-mediated inflammatory diseases. Its recurring updates center on abdakibart (AVTX-009), an anti-IL-1β monoclonal antibody evaluated in hidradenitis suppurativa, including LOTUS trial results, safety and efficacy disclosures, and program development plans.
Company news also covers financial results, investor presentations and conferences, equity compensation grants, public financing activity involving common stock and pre-funded warrants, and milestone obligations tied to the AlmataBio acquisition. These updates connect Avalo's clinical pipeline, capital needs, and governance actions to its public-company reporting cycle.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Avalo Therapeutics (AVTX) announced the completion of enrollment in the Phase 2 PEAK Trial for AVTX-002, targeting non-eosinophilic asthma, with topline data expected in Q2 2023. As of December 31, 2022, the company reported cash reserves of approximately $13 million and a significant decrease in total revenues to $18 million compared to 2021. Operating expenses were reduced by $32 million, primarily through a focus on lead assets and cost-cutting measures. Despite these improvements, the net loss for 2022 was $41.6 million, leading to a net loss per share of $4.43. The company aims for a transformative 2023 with upcoming pivotal trial data.
Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced that Garry A. Neil, M.D., President and CEO, will present virtually at Oppenheimer's 33rd Annual Healthcare Conference on March 13, 2023, at 1:20 p.m. ET. Investors can access the live webcast through the Company’s website under the 'News/Events' section. Avalo Therapeutics focuses on developing therapies that target immune dysregulation via the LIGHT network, which is implicated in autoimmune and inflammatory conditions. The firm aims to mitigate immune dysregulation by reducing LIGHT levels in affected individuals.
Avalo Therapeutics,Inc. (NASDAQ: AVTX) announced a public offering of 3,770,000 shares of its common stock and warrants at $3.98 per unit. The warrants, with a one-year term, have an exercise price of $5.00. The offering is expected to raise approximately $15 million before expenses and is scheduled to close on February 7, 2023. The offering is conducted under a shelf registration statement effective since March 19, 2021. SVB Securities and RBC Capital Markets are the joint bookrunning managers. This announcement is pivotal for investors as it reflects Avalo's capital-raising strategy to support its clinical pipeline.
Avalo Therapeutics, Inc. (NASDAQ: AVTX) has initiated a proposed underwritten public offering of its common stock and warrants. The offering will be conducted under a previously filed shelf registration statement with the SEC. SVB Securities and RBC Capital Markets are serving as joint bookrunning managers for this offering. The specific terms and size remain undisclosed and are subject to market conditions. The final details will be outlined in a prospectus supplement to be filed with the SEC. Avalo focuses on developing therapies for immune dysregulation targeting the LIGHT network, which is crucial in various autoimmune and inflammatory conditions.